Literature DB >> 26303888

Differential effects of N-acetyl-aspartyl-glutamate on synaptic and extrasynaptic NMDA receptors are subunit- and pH-dependent in the CA1 region of the mouse hippocampus.

Pamela Khacho1, Boyang Wang1, Nina Ahlskog1, Elitza Hristova1, Richard Bergeron2.   

Abstract

Ischemic strokes cause excessive release of glutamate, leading to overactivation of N-methyl-d-aspartate receptors (NMDARs) and excitotoxicity-induced neuronal death. For this reason, inhibition of NMDARs has been a central focus in identifying mechanisms to avert this extensive neuronal damage. N-acetyl-aspartyl-glutamate (NAAG), the most abundant neuropeptide in the brain, is neuroprotective in ischemic conditions in vivo. Despite this evidence, the exact mechanism underlying its neuroprotection, and more specifically its effect on NMDARs, is currently unknown due to conflicting results in the literature. Here, we uncover a pH-dependent subunit-specific action of NAAG on NMDARs. Using whole-cell electrophysiological recordings on acute hippocampal slices from adult mice and on HEK293 cells, we found that NAAG increases synaptic GluN2A-containing NMDAR EPSCs, while effectively decreasing extrasynaptic GluN2B-containing NMDAR EPSCs in physiological pH. Intriguingly, the results of our study further show that in low pH, which is a physiological occurrence during ischemia, NAAG depresses GluN2A-containing NMDAR EPSCs and amplifies its inhibitory effect on GluN2B-containing NMDAR EPSCs, as well as upregulates the surface expression of the GluN2A subunit. Altogether, our data demonstrate that NAAG has differential effects on NMDAR function based on subunit composition and pH. These findings suggest that the role of NAAG as a neuroprotective agent during an ischemic stroke is likely mediated by its ability to reduce NMDAR excitation. The inhibitory effect of NAAG on NMDARs and its enhanced function in acidic conditions make NAAG a prime therapeutic agent for the treatment of ischemic events.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  2-PMPA; Biotinylation; Electrophysiology; Hippocampus; N-acetyl-aspartyl-glutamate (NAAG); NMDA receptors; Neuroprotection; Protons

Mesh:

Substances:

Year:  2015        PMID: 26303888     DOI: 10.1016/j.nbd.2015.08.017

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  14 in total

1.  Local enema treatment to inhibit FOLH1/GCPII as a novel therapy for inflammatory bowel disease.

Authors:  Abhijit A Date; Rana Rais; Taarika Babu; Jairo Ortiz; Pranjali Kanvinde; Ajit G Thomas; Sarah C Zimmermann; Alexandra J Gadiano; Gilad Halpert; Barbara S Slusher; Laura M Ensign
Journal:  J Control Release       Date:  2017-01-31       Impact factor: 9.776

Review 2.  A role for N-acetylaspartylglutamate (NAAG) and mGluR3 in cognition.

Authors:  Joseph H Neale; Rafal Olszewski
Journal:  Neurobiol Learn Mem       Date:  2019-01-07       Impact factor: 2.877

3.  Maternal inflammation leads to impaired glutamate homeostasis and up-regulation of glutamate carboxypeptidase II in activated microglia in the fetal/newborn rabbit brain.

Authors:  Zhi Zhang; Bassam Bassam; Ajit G Thomas; Monica Williams; Jinhuan Liu; Elizabeth Nance; Camilo Rojas; Barbara S Slusher; Sujatha Kannan
Journal:  Neurobiol Dis       Date:  2016-06-17       Impact factor: 5.996

4.  FOLH1/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities.

Authors:  Rana Rais; Weiwei Jiang; Huihong Zhai; Krystyna M Wozniak; Marigo Stathis; Kristen R Hollinger; Ajit G Thomas; Camilo Rojas; James J Vornov; Michael Marohn; Xuhang Li; Barbara S Slusher
Journal:  JCI Insight       Date:  2016-08-04

Review 5.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

6.  A role for the locus coeruleus in the analgesic efficacy of N-acetylaspartylglutamate peptidase (GCPII) inhibitors ZJ43 and 2-PMPA.

Authors:  Takahiro Nonaka; Toshihiko Yamada; Tatsuhiro Ishimura; Daiying Zuo; John R Moffett; Joseph H Neale; Tatsuo Yamamoto
Journal:  Mol Pain       Date:  2017-01       Impact factor: 3.395

7.  Pretreatment with mGluR2 or mGluR3 Agonists Reduces Apoptosis Induced by Hypoxia-Ischemia in Neonatal Rat Brains.

Authors:  Ewelina Bratek-Gerej; Agnieszka Bronisz; Apolonia Ziembowicz; Elzbieta Salinska
Journal:  Oxid Med Cell Longev       Date:  2021-03-06       Impact factor: 6.543

8.  NAAG Peptidase Inhibitors Act via mGluR3: Animal Models of Memory, Alzheimer's, and Ethanol Intoxication.

Authors:  Rafal T Olszewski; Karolina J Janczura; Tomasz Bzdega; Elise K Der; Faustino Venzor; Brennen O'Rourke; Timothy J Hark; Kirsten E Craddock; Shankar Balasubramanian; Charbel Moussa; Joseph H Neale
Journal:  Neurochem Res       Date:  2017-03-11       Impact factor: 3.996

9.  Dendritic Localization and Exocytosis of NAAG in the Rat Hippocampus.

Authors:  K Nordengen; C Morland; B S Slusher; V Gundersen
Journal:  Cereb Cortex       Date:  2020-03-14       Impact factor: 5.357

10.  Glutamate Attenuates the Survival Property of IGFR through NR2B Containing N-Methyl-D-aspartate Receptors in Cortical Neurons.

Authors:  Xia Zhao; Chao Han; Zhiwen Zeng; Linlin Liu; Haitao Wang; Jiangping Xu; Zhong-Ping Feng; Peter J Little; Remi Quirion; Wenhua Zheng
Journal:  Oxid Med Cell Longev       Date:  2020-08-11       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.